Latest Aggregates News

Pacific Current Group reports a 6.1% increase in total Funds Under Management to A$30 billion as of December 31, 2024, despite a decline in USD-denominated assets and exits from two boutique managers.

Alterity Therapeutics has reported positive Phase 2 results for ATH434, showing significant slowing of Multiple System Atrophy progression and a favorable safety profile. The trial demonstrated clinical benefits alongside reductions in brain iron accumulation, a key disease driver.

Argenica Therapeutics has dosed 80% of patients in its Phase 2 stroke trial and gained FDA orphan drug designations for its second candidate, ARG-006. The company reports a cash-positive quarter with $15 million in reserves.

Neurizon Therapeutics reports encouraging 8-month interim results for its ALS drug NUZ-001, secures Orphan Medicinal Product Designation in Europe, and raises $885,000 through a share placement, maintaining a robust $14 million cash position.

RemSense Technologies delivered a cashflow positive Q2 FY2025, driven by a 78% surge in customer receipts and successful execution of major global contracts. The company’s virtualplant platform continues to gain traction across mining, oil and gas, and new industrial sectors.

Singular Health has secured a pivotal MoU with Miami-based Provider Network Solutions and raised $3.7 million to propel its 3Dicom software towards a US commercial pilot, supported by the appointment of esteemed radiologist Dr. Ronny Low.

Astral Resources has reported its most significant diamond drilling results to date at the Theia Deposit within the Mandilla Gold Project, with drill-hole MDRCD918 delivering an exceptional 1,079 gram-metres of gold mineralisation. This breakthrough is expected to underpin an upgrade of the resource classification ahead of a Mineral Resource Estimate update scheduled for March 2025.

5E Advanced Materials has entered a pivotal Restructuring Support Agreement with its primary lenders to equitize $63.5 million in convertible notes and secure up to $30 million in funding. The transaction, subject to shareholder approval, aims to strengthen the balance sheet and advance the company toward its Final Investment Decision.